Switching to macitentan in pulmonary arterial hypertension

I. Tsagkaris (Athens, Greece), E. Vrigkou (Athens, Greece), D. Konstantonis (Athens, Greece), F. Frantzeskaki (Athens, Greece), A. Pappas (Athens, Greece), K. Ntaï (Athens, Greece), E. Stagaki (Athens, Greece), A. Armaganidis (Athens, Greece), S. Orfanos (Athens, Greece)

Source: International Congress 2018 – Pulmonary hypertension: therapy
Session: Pulmonary hypertension: therapy
Session type: Thematic Poster
Number: 3045
Disease area: Pulmonary vascular diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
I. Tsagkaris (Athens, Greece), E. Vrigkou (Athens, Greece), D. Konstantonis (Athens, Greece), F. Frantzeskaki (Athens, Greece), A. Pappas (Athens, Greece), K. Ntaï (Athens, Greece), E. Stagaki (Athens, Greece), A. Armaganidis (Athens, Greece), S. Orfanos (Athens, Greece). Switching to macitentan in pulmonary arterial hypertension. 3045

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: